- 01Lifespan evidence is preclinical; human evidence is about tolerability
Rapamycin extended median life by up to 26 percent in preclinical studies (Miller 2014), but human trials so far only show that weekly low doses are tolerable for about a year; no human study has measured lifespan.
- 02Transplant risks and weekly-use risks come from different doses
The label's boxed warning and side-effect rates come from daily doses combined with other immune drugs; weekly longevity doses have fewer reported problems, measured in far smaller studies.
- 03mTORC1 is the target, mTORC2 is the side effect
Rapamycin blocks mTORC1 quickly and mTORC2 only with steady exposure, so weekly dosing tries to keep the longevity effect while sparing insulin signalling.
Rapamycin lengthens life in preclinical studies, but no human study has shown that it slows aging. Started late in life, it raised late-life survival by 9 percent in males and 14 percent in females 1, and at higher doses median life rose by up to 23 and 26 percent 7. The human evidence answers a smaller question, whether weekly low doses are tolerable for about a year, and it says little yet about aging itself 3. Keeping those two bodies of evidence apart tells you what rapamycin can and cannot promise, and which blood tests matter if you and a prescriber ever weigh it up.
What is rapamycin?
Rapamycin is a compound made by a soil bacterium, Streptomyces hygroscopicus, found in a sample collected on Easter Island (Rapa Nui, which gave the drug its name) during a 1964 expedition. Researchers at Ayerst described it in 1975 as an antifungal. Its stronger effect turned out to be on the immune system, and the FDA approved it in 1999 as Rapamune to prevent rejection after kidney transplant, and later for lymphangioleiomyomatosis (LAM), a rare lung disease 6. Sirolimus also coats some heart stents, where it stops arteries re-narrowing. Close relatives called rapalogs, such as everolimus and temsirolimus, are used in transplant medicine and cancer.
Rapamycin is a prescription drug, so no supplement legally contains it. Products sold as natural rapamycin or mTOR support are usually plant extracts and are not a legal source of rapamycin. No drug is FDA-approved to treat aging, so a doctor who prescribes rapamycin for longevity is prescribing it off-label, which is legal but means no regulator has judged the benefit against the risk for that use.
How rapamycin works: mTOR in plain words
mTOR (short for mechanistic target of rapamycin) is a protein that senses food, insulin and amino acids and tells the cell whether to build or to repair. When mTOR is on, cells make protein and grow. When it is off, cells lean toward autophagy, the process of breaking down and recycling worn-out parts. mTOR works inside two separate complexes. mTORC1 drives growth and puts the brake on autophagy, and it is the complex longevity researchers want to dial down. mTORC2 helps the liver and muscles respond to insulin, and blocking it is what raises blood sugar.
Rapamycin blocks mTORC1 quickly. mTORC2 is affected only with longer, steady exposure, and that difference in timing is why longevity users take rapamycin once a week instead of daily. In 2012 Dudley Lamming and colleagues showed that the rise in blood sugar seen with daily rapamycin comes from losing mTORC2, and that the longevity benefit runs through mTORC1, so the two can be pulled apart 2.
Why daily rapamycin raises blood sugar, and why weekly dosing exists
Sirolimus has a mean half-life of about 62 hours in transplant patients, so half of a dose is gone in roughly two and a half days 6. The chart below shows what that means across one week.
What the research shows: preclinical studies vs people
The preclinical record is strong by the standards of aging research. The National Institute on Aging's Interventions Testing Program, which runs each test at three separate sites, started rapamycin at 600 days of age, roughly the equivalent of 60 human years. The age reached by the longest-lived 10 percent rose 9 percent in males and 14 percent in females 1. A follow-up found the effect grew with dose, reaching 23 percent longer median life (the age by which half had died) in males and 26 percent in females at the highest dose 7. In pet dogs, the Dog Aging Project's TRIAD trial is still running and has no lifespan result yet.
The human record is thinner, and none of it measures lifespan. In 2014, Joan Mannick's team gave the rapalog everolimus to 218 adults over 65 for 6 weeks and saw about a 20 percent better antibody response to a flu vaccine 9. A later phase 3 trial of a different mTOR inhibitor, RTB101, did not reduce respiratory illnesses in older adults, the main thing it set out to show 5. The immune effect of mTOR inhibitors depends on dose: transplant doses suppress immunity, while the low, short courses in these trials were tested to see whether they could improve it. A 2024 systematic review of 19 human studies found gains in some immune, cardiovascular and skin measures, no significant effect on hormonal, muscle or brain measures, and more infections plus higher total cholesterol, LDL and triglycerides in people who already had aging-related diseases 4.
There are good reasons the preclinical gains may shrink in people. The lab strains in these programs die mostly of cancer, and rapamycin is an anti-cancer drug, so part of their longer life may come from delayed tumors. People die more often of heart disease and stroke, where rapamycin's tendency to raise cholesterol and triglycerides could pull in the other direction 4. Preclinical doses also ran continuously in food for much of life, a pattern nobody uses in people because of its effect on blood sugar 2.
| Study | Who | What was given | What changed | Type of evidence |
|---|---|---|---|---|
| Harrison 2009 1 | Genetically diverse lab strains, started at 600 days | Rapamycin in food | 9% (males) and 14% (females) longer late-life survival | Preclinical, lifespan |
| Miller 2014 7 | Same program, three doses | Rapamycin in food | Up to 23% and 26% longer median life | Preclinical, lifespan |
| Mannick 2014 9 | 218 adults over 65 | Everolimus for 6 weeks | About 20% better flu-vaccine antibody response | Human randomized trial, vaccine response only |
| Mannick 2021 5 | Older adults, phase 3 | RTB101 daily | Did not reduce respiratory illnesses, its main goal | Human randomized trial, illness rates |
| PEARL 2025 3 | 114 healthy adults, 48 weeks | Placebo, or 5 mg or 10 mg weekly of compounded (pharmacy-made) rapamycin | Visceral fat unchanged; side effects similar to placebo | Human randomized trial, safety and body measures |
| Kaeberlein 2023 8 | 333 off-label users vs 172 non-users | Self-chosen doses, mostly weekly | Mouth ulcers most common; few serious problems reported | Human survey, self-reported |
| Lee 2024 4 | 19 human studies | Rapamycin or rapalogs | Some immune, heart and skin gains; more infections and lipids in sick groups | Systematic review |
PEARL is the trial most often quoted for longevity use. The 114 healthy adults who completed it took placebo, 5 mg or 10 mg of compounded rapamycin (made up by a compounding pharmacy rather than a branded or generic tablet) once a week for 48 weeks. Adverse events were similar across all three groups, and blood biomarker changes stayed inside normal ranges 3. Its main outcome, visceral fat (the fat packed around the organs, measured with a DXA body scan), did not change. Lean tissue mass and self-reported pain improved only in women on 10 mg, a small subgroup, and self-reported emotional well-being and general health improved on 5 mg 3.
Low-dose, intermittent rapamycin administration over 48 weeks is relatively safe in healthy, normative-aging adults.
How much rapamycin do people take for longevity?
No dose of rapamycin is established for longevity, and the figures below describe what has been studied, not what anyone should take. Transplant patients take it every day alongside other immune drugs, with doses adjusted to a target blood level 6. Off-label longevity use runs once a week: PEARL tested 5 mg and 10 mg weekly 3, and most users in the 333-person survey also took a weekly dose, some with planned breaks 8. Absorption varies widely between people, between compounded and generic tablets, and with fat in a meal, which is why the label tells patients to take it the same way each time, always with food or always without 6. Choosing and adjusting a dose belongs with a prescriber who is ordering your blood tests.
| Feature | Transplant use (on-label) | Longevity use (off-label) |
|---|---|---|
| How often | Every day | Once a week in trials and surveys |
| Dose studied | Daily doses adjusted to a target trough (the lowest level, just before the next dose) | 5 mg or 10 mg weekly in PEARL |
| Other drugs | Usually combined with other immunosuppressants | Usually taken alone |
| Blood level target | Yes, a set trough range | None established |
| Where side-effect rates come from | Large transplant trials on the label | Small trials and a self-reported survey |
| What it means for you | Label risk rates reflect sick, heavily treated patients | Risks look lower but are less well measured |
A sirolimus trough level is a blood test taken right before the next dose, measuring the lowest point in the cycle. Transplant teams use it to keep the drug in a target range. For weekly longevity use there is no agreed target, so a trough mainly shows whether a given person absorbs the drug at all, and it only makes sense if it is drawn at the same point in the weekly cycle every time.
How sirolimus is taken, from the label and the trials
Rapamycin side effects and who should not take it
At weekly low doses, mouth ulcers (stomatitis) are the side effect people report most, in the 333-person survey 8 and on the label. Other effects seen at low doses include a modest rise in cholesterol and triglycerides, slightly higher fasting glucose in some people, slower wound healing, more minor infections, and acne or rash. In PEARL these stayed close to placebo rates over 48 weeks 3. The transplant label lists a longer set of problems at daily doses, and its boxed warning reads: "Increased susceptibility to infection and the possible development of lymphoma" 6.
| Effect | At weekly low doses (trials, survey) | At daily transplant doses (label) |
|---|---|---|
| Mouth ulcers | Most commonly reported | Listed adverse reaction |
| Cholesterol and triglycerides | Small rises in some people | Rises requiring treatment, more often than with comparators |
| Blood sugar | Small rises possible | New-onset diabetes reported |
| Infections | Mostly minor, similar to placebo in PEARL | Boxed warning for serious infection |
| Blood counts | Usually within range | Low platelets and anemia listed |
| Wound healing | Slower healing reported | Impaired or delayed healing, wound breakdown |
| Kidneys and swelling | Rarely reported | Raised creatinine, protein in urine, leg swelling |
| Allergic swelling (angioedema) | Not well measured | Reported; risk higher with ACE inhibitors |
| Cancer | No signal in short trials | Boxed warning for lymphoma; higher skin cancer risk, so the label advises limiting sun exposure |
The label column comes from the sirolimus prescribing information 6; the low-dose column comes from PEARL 3 and the 333-person survey 8.
Drug interactions to tell a prescriber about
Sirolimus is broken down by the liver enzyme CYP3A4 and pumped out of cells by P-glycoprotein, so anything that blocks or speeds up those two changes the blood level 6. Strong blockers such as ketoconazole, itraconazole, voriconazole and clarithromycin can push sirolimus levels up sharply, and the label advises against combining them. Inducers such as rifampin and rifabutin pull levels down. Cyclosporine, another transplant drug, raises sirolimus levels. Taking sirolimus with an ACE inhibitor, a common blood pressure drug such as lisinopril or ramipril, raises the risk of angioedema, a sudden swelling of the face, lips, tongue or throat 6. Tell any doctor or pharmacist you take rapamycin before starting a new antibiotic, antifungal or blood pressure medicine. Live vaccines (for example the nasal flu vaccine, yellow fever and MMR) should be avoided during treatment. Because the label warns that sirolimus can slow wound healing, any planned surgery or dental surgery is something to raise with the prescriber well beforehand; transplant patients should not pause it without their transplant team 6.
Because grapefruit juice inhibits the CYP3A4-mediated metabolism of sirolimus, it must not be taken with sirolimus.Sirolimus US prescribing information, section 7.3 6
Who should not take rapamycin for longevity
This list is about off-label longevity use. If you take sirolimus after a transplant or for LAM, none of it is a reason to stop; your transplant or lung team decides any change.
- Anyone pregnant, breastfeeding or trying to conceive; the label advises highly effective contraception during treatment and for 12 weeks after stopping 6.
- Anyone with an active infection, or a weakened immune system from illness or other medicines.
- People with poorly controlled diabetes or very high cholesterol or triglycerides, since rapamycin can raise all three.
- Anyone with liver disease, since the label lowers the dose for liver impairment 6.
- Anyone who has had an allergic reaction to sirolimus 6, or to a related drug such as everolimus.
- Anyone with surgery, dental surgery or an open wound coming up.
- Anyone taking a strong CYP3A4 blocker or inducer that cannot be stopped.
Blood tests before and during rapamycin
For anyone on rapamycin, the most useful comparison is their own pre-treatment baseline. A triglyceride level of 140 mg/dL (1.6 mmol/L) is inside range, but if it was 70 mg/dL before treatment, it has doubled, and that is worth a conversation. No professional guideline sets a monitoring schedule for off-label longevity use. The schedule below is one example of how a prescriber might space tests, drawn from what the label monitors in transplant patients and what PEARL measured 3 6; the prescriber sets the actual timing.
| When | Tests | Why |
|---|---|---|
| Before starting | Lipid panel with ApoB, fasting glucose, HbA1c, fasting insulin, CBC with differential (full blood count including each white-cell type), liver enzymes, creatinine and eGFR (an estimate of kidney filtering) | Sets the baseline every later result is compared against |
| About 6 to 8 weeks after starting or any dose change | Same panel; trough level if the prescriber uses one | Catches early lipid, glucose and blood-count shifts |
| Every 3 months in the first year | Same panel | Shows whether early changes settle, persist or grow |
| After the first year | As the prescriber decides, often every 6 months | Tracks long-term drift |
Each marker answers a question about a known rapamycin effect. Small rises in triglycerides, LDL or ApoB and a slight rise in fasting glucose or insulin are common on rapamycin and are worth tracking rather than fearing 3 6. The third column lists the changes to bring to a prescriber promptly instead of waiting for the next routine review.
| Marker | Why it is checked on rapamycin | Bring to a prescriber promptly if | US unit (SI unit) |
|---|---|---|---|
| ApoB and LDL cholesterol | Rapamycin can raise cholesterol-carrying particles; ApoB vs LDL explains why ApoB is the cleaner read | It climbs from baseline on two draws in a row | mg/dL (mmol/L for LDL; g/L for ApoB) |
| Triglycerides | Often the first lipid to rise | It keeps climbing across two or more draws | mg/dL (mmol/L) |
| Fasting glucose, HbA1c, fasting insulin | The mTORC2 effect on insulin | HbA1c moves into the prediabetes range, or glucose keeps rising | mg/dL (mmol/L); %; µIU/mL (pmol/L) |
| Platelets, white count, neutrophils | Bone marrow suppression and infection risk | Any of them falls below the lab's range | x10^3/µL (x10^9/L) |
| ALT | The liver processes sirolimus | It climbs above the lab's range | U/L |
| Creatinine and eGFR | Kidney effects seen at transplant doses | Creatinine rises or eGFR falls from baseline | mg/dL (µmol/L); mL/min/1.73m² |
Markers to track on rapamycin
Two numbers are easier to follow as calculations. HOMA-IR combines fasting glucose and fasting insulin into one insulin-resistance score that can be compared with your baseline. The absolute neutrophil count calculator turns a white count and a neutrophil percentage into the number that matters for infection risk.
CalculatorHOMA-IR calculatorTurns fasting glucose and fasting insulin into one insulin-resistance number to compare against the pre-rapamycin baseline.Work it out Small habits make the trend readable. Fast for 10 to 12 hours before the lipid and glucose draw (see fasting before a blood test), test on the same day of the weekly cycle each time, and use the same lab where possible. One high value is a reason to ask about a repeat test, often 4 to 6 weeks later on the same day of the cycle; trends beat single readings explains why. If lipids rise, diet comes first (see foods that lower cholesterol). The sirolimus label notes that raised lipids often needed treatment in transplant patients, and prescribers sometimes add a statin when LDL or ApoB climbs 6. For the full read of each panel, see how to read your lipid panel, blood sugar explained, the CBC explained, liver enzymes explained and kidney function explained.
Free, no accountRead your blood testHave a baseline panel and a follow-up from after starting rapamycin? Read every line of both, free, and see what moved.Read my results
Rapamycin vs metformin and other longevity options
Rapamycin is often weighed against metformin, the other generic drug repurposed for longevity, and against exercise and fasting, which move mTOR without a drug. The three differ most in the quality of their human evidence.
mTOR also responds to everyday habits. A protein-rich meal and a resistance-training session switch mTORC1 on, which is how muscle grows, and fasting or a calorie deficit switches it down. Rapamycin pushes mTORC1 lower and for longer than any habit can, which is where both its preclinical power and its side effects come from. Exercise moves mTOR on and off in a rhythm and has the human outcome data rapamycin lacks.
| Rapamycin | Metformin | Exercise | |
|---|---|---|---|
| Main target | mTORC1 | AMPK (an energy-sensing enzyme) and liver glucose output | Many, including mTOR, AMPK and insulin sensitivity |
| Best lifespan evidence | Consistent preclinical gains 1 7 | Mixed preclinical results; TAME (a proposed trial of metformin in older adults) not reported | Human cohort studies (observational) |
| Proven to extend human life | No | No | Not by a trial; the strongest observational case of the three |
| Access | Prescription, off-label | Prescription, off-label for longevity | None needed |
| Main trade-off | Mouth ulcers, lipids, glucose, infection risk | Stomach upset, lower B12 | Injury risk, time |
Compounds people compare with rapamycin
For how rapamycin fits with sleep, training, blood pressure and the rest of a longevity plan, see the longevity guide. For how one well-known longevity physician uses blood tests, including ApoB, see Peter Attia's blood tests, and for the closer look at metformin against a supplement rival, see berberine vs metformin.
Citations
- Harrison DE et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature, 2009;460:392-395
- Lamming DW et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science, 2012;335:1638-1643
- Moel M et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY), 2025;17(4):908-936
- Lee DJW, Hodzic Kuerec A, Maier AB. Targeting ageing with rapamycin and its derivatives in humans: a systematic review. Lancet Healthy Longevity, 2024;5(2):e152-e162
- Mannick JB et al. Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials. Lancet Healthy Longevity, 2021;2(5):e250-e262
- Sirolimus tablets (generic Rapamune) US prescribing information, DailyMed, US National Library of Medicine
- Miller RA et al. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell, 2014;13(3):468-477
- Kaeberlein TL et al. Evaluation of off-label rapamycin use to promote healthspan in 333 adults. GeroScience, 2023;45(5):2757-2768
- Mannick JB et al. mTOR inhibition improves immune function in the elderly. Science Translational Medicine, 2014;6(268):268ra179
- Arriola Apelo SI et al. Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system. Aging Cell, 2016;15(1):28-38
Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.










